Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATOS NASDAQ:CASI NASDAQ:EQ NASDAQ:FATE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATOSAtossa Genetics$0.82+0.5%$0.82$0.55▼$1.66$105.69M1.1457,343 shs556,220 shsCASICASI Pharmaceuticals$2.01-3.8%$1.88$1.09▼$7.50$25.70M0.7762,081 shs286,475 shsEQEquillium$1.63-4.7%$1.07$0.27▼$2.35$101.75M1.582.59 million shs951,583 shsFATEFate Therapeutics$0.95-0.5%$1.09$0.66▼$4.20$110.23M2.211.32 million shs841,705 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATOSAtossa Genetics+0.46%+1.86%+5.86%+2.34%-45.56%CASICASI Pharmaceuticals-3.83%-14.10%-15.55%+47.79%-70.83%EQEquillium-4.68%-10.93%+42.98%+405.43%+89.53%FATEFate Therapeutics-0.53%-2.98%-12.78%-21.43%-75.99%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATOSAtossa Genetics$0.82+0.5%$0.82$0.55▼$1.66$105.69M1.1457,343 shs556,220 shsCASICASI Pharmaceuticals$2.01-3.8%$1.88$1.09▼$7.50$25.70M0.7762,081 shs286,475 shsEQEquillium$1.63-4.7%$1.07$0.27▼$2.35$101.75M1.582.59 million shs951,583 shsFATEFate Therapeutics$0.95-0.5%$1.09$0.66▼$4.20$110.23M2.211.32 million shs841,705 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATOSAtossa Genetics+0.46%+1.86%+5.86%+2.34%-45.56%CASICASI Pharmaceuticals-3.83%-14.10%-15.55%+47.79%-70.83%EQEquillium-4.68%-10.93%+42.98%+405.43%+89.53%FATEFate Therapeutics-0.53%-2.98%-12.78%-21.43%-75.99%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATOSAtossa Genetics 3.33Buy$6.17650.20% UpsideCASICASI Pharmaceuticals 3.00Buy$4.0099.00% UpsideEQEquillium 2.00Hold$1.00-38.65% DownsideFATEFate Therapeutics 2.14Hold$3.30247.11% UpsideCurrent Analyst Ratings BreakdownLatest CASI, EQ, FATE, and ATOS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025CASICASI PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.008/13/2025FATEFate TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$4.00 ➝ $2.50(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATOSAtossa GeneticsN/AN/AN/AN/A$0.57 per shareN/ACASICASI Pharmaceuticals$28.54M0.87N/AN/A$0.12 per share16.75EQEquillium$41.10M2.36N/AN/A$0.54 per share3.02FATEFate Therapeutics$13.63M8.04N/AN/A$2.80 per share0.34Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATOSAtossa Genetics-$25.50M-$0.23N/AN/AN/AN/A-40.28%-37.10%11/11/2025 (Estimated)CASICASI Pharmaceuticals-$39.26M-$2.89N/A∞N/A-148.55%-972.55%-99.07%11/12/2025 (Estimated)EQEquillium-$8.07M-$0.56N/AN/AN/A-19.62%-139.56%-90.56%11/12/2025 (Estimated)FATEFate Therapeutics-$186.26M-$1.45N/AN/AN/A-2,025.05%-50.95%-36.76%11/11/2025 (Estimated)Latest CASI, EQ, FATE, and ATOS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/29/2025Q2 2025CASICASI Pharmaceuticals-$0.47-$0.86-$0.39-$0.86$6.28 million$4.18 million8/14/2025Q2 2025EQEquillium-$0.14-$0.16-$0.02-$0.16N/AN/A8/12/2025Q2 2025ATOSAtossa Genetics-$0.06-$0.07-$0.01-$0.07N/AN/A8/12/2025Q2 2025FATEFate Therapeutics-$0.35-$0.29+$0.06-$0.29$1.16 million$1.91 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATOSAtossa GeneticsN/AN/AN/AN/AN/ACASICASI PharmaceuticalsN/AN/AN/AN/AN/AEQEquilliumN/AN/AN/AN/AN/AFATEFate TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATOSAtossa GeneticsN/A9.179.17CASICASI PharmaceuticalsN/A0.480.39EQEquilliumN/A1.651.65FATEFate TherapeuticsN/A8.048.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATOSAtossa Genetics12.74%CASICASI Pharmaceuticals22.23%EQEquillium27.05%FATEFate Therapeutics97.54%Insider OwnershipCompanyInsider OwnershipATOSAtossa Genetics8.70%CASICASI Pharmaceuticals21.24%EQEquillium30.30%FATEFate Therapeutics5.51%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATOSAtossa Genetics8129.17 million117.93 millionOptionableCASICASI Pharmaceuticals18012.30 million9.69 millionOptionableEQEquillium4059.50 million41.47 millionNot OptionableFATEFate Therapeutics550115.33 million108.98 millionOptionableCASI, EQ, FATE, and ATOS HeadlinesRecent News About These CompaniesJacobs Levy Equity Management Inc. Acquires 616,336 Shares of Fate Therapeutics, Inc. $FATESeptember 13, 2025 | marketbeat.comLeerink Partners Sticks to Its Buy Rating for Fate Therapeutics (FATE)September 11, 2025 | theglobeandmail.comWalleye Capital LLC Decreases Stock Position in Fate Therapeutics, Inc. $FATESeptember 9, 2025 | marketbeat.comNuveen LLC Invests $300,000 in Fate Therapeutics, Inc. $FATESeptember 8, 2025 | marketbeat.comResearch Analysts Offer Predictions for FATE Q3 EarningsSeptember 7, 2025 | marketbeat.comFate Therapeutics, Inc. (NASDAQ:FATE) Receives $3.30 Consensus Price Target from BrokeragesSeptember 7, 2025 | americanbankingnews.comLeerink Partnrs Brokers Increase Earnings Estimates for FATESeptember 7, 2025 | americanbankingnews.comFate Therapeutics, Inc. (NASDAQ:FATE) Given Average Recommendation of "Hold" by BrokeragesSeptember 5, 2025 | marketbeat.comFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)September 3, 2025 | globenewswire.comFate Therapeutics: Recent Update Met With Selling, But Positives ExistAugust 29, 2025 | seekingalpha.comFY2026 EPS Estimates for FATE Decreased by Cantor FitzgeraldAugust 24, 2025 | marketbeat.comFate Therapeutics (NASDAQ:FATE) Stock Rating Upgraded by Wall Street ZenAugust 19, 2025 | marketbeat.comQ3 EPS Forecast for Fate Therapeutics Raised by AnalystAugust 17, 2025 | marketbeat.comFate Therapeutics Second Quarter 2025 Earnings: Beats ExpectationsAugust 14, 2025 | finance.yahoo.comFate Therapeutics price target lowered to $2.50 from $4 at Wells FargoAugust 13, 2025 | msn.comFate Therapeutics reports Q2 EPS (29c), consensus (34c)August 12, 2025 | msn.comFate Therapeutics Announces Corporate Restructuring PlanAugust 12, 2025 | msn.comFate Therapeutics: Q2 Earnings SnapshotAugust 12, 2025 | sfgate.comFate Therapeutics to Cut 12% of Workforce, 2Q Loss NarrowsAugust 12, 2025 | marketwatch.comFate Therapeutics (FATE) Reports Q2 Loss, Beats Revenue EstimatesAugust 12, 2025 | zacks.comFate Therapeutics Reports Second Quarter 2025 Financial Results and Business UpdatesAugust 12, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines2 Data Center REITs That Look Good in Any PortfolioBy Sam Quirke | September 8, 2025Intel's New Buyers Mean Good News for Taiwan Semiconductor StockBy Gabriel Osorio-Mazilli | August 22, 2025Equal Weight ETFs: Hidden Upside in Today’s MarketBy Gabriel Osorio-Mazilli | August 23, 2025Taiwan Semiconductor Falls on China News—Buy The Dip?By Gabriel Osorio-Mazilli | September 3, 2025Dueling Insider Moves: Heavy Buying Here, Big Selling ThereBy Leo Miller | September 2, 2025CASI, EQ, FATE, and ATOS Company DescriptionsAtossa Genetics NASDAQ:ATOS$0.82 +0.00 (+0.46%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$0.83 +0.01 (+1.22%) As of 09/16/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.CASI Pharmaceuticals NASDAQ:CASI$2.01 -0.08 (-3.83%) Closing price 09/16/2025 03:59 PM EasternExtended Trading$2.06 +0.06 (+2.74%) As of 09/16/2025 07:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.Equillium NASDAQ:EQ$1.63 -0.08 (-4.68%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$1.68 +0.05 (+2.76%) As of 09/16/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.Fate Therapeutics NASDAQ:FATE$0.95 -0.01 (-0.53%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$0.97 +0.02 (+1.61%) As of 09/16/2025 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
